Dementia references
Boston PF, Bennett A, Horrobin DF, Bennett CN. Ethyl-EPA in Alzheimer’s disease–a pilot study. Prostaglandins Leukot Essent Fatty Acids. 2004 71:341-6.
Das UN. Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression, dementia, and Alzheimer’s disease–but how and why? Prostaglandins Leukot Essent Fatty Acids. 2008 8:11-9.
Florent-Béchard S, Desbène C, Garcia P, Allouche A, Youssef I, Escanyé MC, Koziel V, Hanse M, Malaplate-Armand C, Stenger C, Kriem B, Yen-Potin FT, Olivier JL, Pillot T, Oster T. The essential role of lipids in Alzheimer’s disease. Biochimie. 2009 91:804-9.
Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N. Food Combination and Alzheimer Disease Risk: A Protective Diet. Arch Neurol. 2010 Apr 12. Ahead of print
Horrobin DF. Food, micronutrients, and psychiatry. Int Psychogeriatr. 2002 14:331-4.
Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol. 2008 65:1582-9.
Kröger E, Verreault R, Carmichael PH, Lindsay J, Julien P, Dewailly E, Ayotte P, Laurin D.Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. Am J Clin Nutr. 2009 90:184-92.
Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin.J Neurosci. 2009 29:9078-89.
Morley JE. Nutrition and the brain. Clin Geriatr Med. 2010 26:89-98
Staehelin HB. Neuronal protection by bioactive nutrients. Int J Vitam Nutr Res. 2008 78:282-5.
Samieri C, Féart C, Letenneur L, Dartigues JF, Pérès K, Auriacombe S, Peuchant E, Delcourt C, Barberger-Gateau P. Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am J Clin Nutr. 2008 88:714-21.
Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY.
The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008 32:1538-44.
Murck H, Manku M. Ethyl-EPA in Huntington disease: potentially relevant mechanism of action. Brain Res Bull. 2007 72:159-64.
Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, Honer WG, Hayden MR, Leavitt BR. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol. 2005 196:266-72.
Puri BK, Bydder GM, Counsell SJ, Corridan BJ, Richardson AJ, Hajnal JV, Appel C, Mckee HM, Vaddadi KS, Horrobin DF. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport. 2002 13:123-6.
Puri BK, Bydder GM, Manku MS, Clarke A, Waldman AD, Beckmann CF.
Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington’s disease. J Int Med Res. 2008 36:896-905.
Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 2005 65:286-92
Puri BK, Tsaluchidu S, Treasaden IH.Serial structural MRI analysis and proton and 31PMR spectroscopy in the investigation of cerebral fatty acids in major depressive disorder, Huntington’s disease, myalgic encephalomyelitis and in forensic schizophrenic patients. World Rev Nutr Diet. 2009 99:31-45.
White B. Dietary fatty acids. Am Fam Physician. 2009 80:345-50. Review.
